---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087059"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:50:05.106907+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Replimune Q1 net loss $49.6M; CERPASS data delayed to early Q4; inks Incyte CSCC trial

## Summary
- Net loss $49.6M in fiscal Q1 vs $42.3M a year ago; cash $539.1M provides runway into H2 2025.
- CERPASS topline data (RP1+Libtayo in CSCC) expected early Q4 2023, delayed from Q3 due to slower independent review.
- IGNYTE full cohort snapshot (N=141) in anti-PD1 failed melanoma on track for Q4 2023; BLA submission planned Q1/Q2 2024.
- Clinical trial collaboration with Incyte to test RP1 + oral PD-L1 INCB99280 in neoadjuvant CSCC; trial to start early 2024, costs shared.
- RP2/RP3 Phase 2 programs: third-line CRC trial initiated; HCC trial expected this quarter; Phase 1 completion in Q3 2023.

## SEC filing metadata
- accession: 0001104659-23-087059
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/0001104659-23-087059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/tm2317748d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087059
- JSON: https://secwatch.observer/filing/0001104659-23-087059.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087059.txt

## Key facts
- Earnings Releases
  Replimune Group, Inc. reported financial results for fiscal first quarter ended June 30, 2023.
  - Period: fiscal first quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the first quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/0001104659-23-087059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.